SUMMARY
UCLA Researchers in the Departments of Bioengineering and School of Medicine and Co-inventors from The National University of Singapore have developed a drug development platform for optimized drug combination and dosage for drug-resistant multiple myeloma patients.
BACKGROUND
Multiple myeloma is a plasma cell malignancy that leads to significant morbidity. Although multiple myeloma remains incurable, advancements in therapeutics have resulted in increased survival time and complete remission for a limited period in patients. While recent developments in molecular targeting therapies have improved outcomes, identification of optimal drug combinations and dosages for individual patients remains a significant challenge. There is a need to develop better methods to identify optimal drug combinations and patient-specific dosages to maximize both efficacy and safety.
INNOVATION
UCLA researchers have developed an experimentally driven phenotypic optimization technology, AI-PRS platform, to rationally and systematically optimize drug combinations and dosages for individual myeloma patients. In a multi-objective fashion, AI-PRS serves as a top-down, experimentally-driven approach that directs a biological system towards a desired phenotype. This method has already been prototyped and successfully test against multiple myeloma cells, including Bortezomib-resistant cells, to identify a series of FDA-approved, AI-PRS-derived optimal therapeutic drug combinations that outperform existing drug combinations. By using patient-centric drug screening, this method serves as a safer, cost and time-effective tool to screen for personalized optimal drug combinations and dosages.
POTENTIAL APPLICATIONS
- Multiple myeloma treatment
- Personalized drug combination development
- Drug combination and dosing optimization
ADVANTAGES
- Highly personalized for individual patients
- Time efficient
- Cost efficient
RELATED MATERIALS
STATUS OF DEVELOPMENT
The AI-PRS platform has been assembled and successfully demonstrated in 30 disease models including clinical tests in cancers, infectious diseases and organ transplants. The clinical trial of the AI-PRS based Multiple myeloma is ongoing at co-inventors’ institution, National University of Singapore.